Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction

BACKGROUND: Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits in using Group 1 PH therapies in these patients, particularly in seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinkamp, Colin A., Shah, Trushil, Bartolome, Sonja, Torres, Fernando, Chin, Kelly M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024797/
https://www.ncbi.nlm.nih.gov/pubmed/33841939
http://dx.doi.org/10.21037/jtd-20-1635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024797/
https://www.ncbi.nlm.nih.gov/pubmed/33841939
http://dx.doi.org/10.21037/jtd-20-1635

Ejemplares similares